Skip to main content

Personalis Inc

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

PSNL$15.88-0.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits, Financial Statement Schedules

(a) Financial Statements and Schedules

The financial statements are set forth under Item 8 of this Annual Report on Form 10-K, as indexed below. Financial statement schedules have been omitted since they either are not required, not applicable, or the information is otherwise included.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Page
Consolidated Balance Sheets70
Consolidated Statements of Operations71
Consolidated Statements of Comprehensive Loss72
Consolidated Statements of Stockholders’ Equity73
Consolidated Statements of Cash Flows74
Notes to Consolidated Financial Statements75
Report of Independent Registered Public Accounting Firm98

(b) Exhibits

Incorporated by Reference
ExhibitNumberDescriptionFormFile No.ExhibitFiling Date
3.1Amended and Restated Certificate of Incorporation of the Registrant.8-K001-389433.16/24/2019
3.2Amended and Restated Bylaws of the Registrant.8-K001-389433.110/31/2022
4.1Description of Securities of Personalis, Inc.10-K001-389434.12/25/2021
4.2Form of Common Stock Certificate of the Registrant.S-1/A333-2317034.16/7/2019
4.3Investment Agreement, dated August 16, 2024, by and between the Registrant and Tempus AI, Inc.8-K001-389434.18/16/2024
4.4Investment Agreement, dated December 19, 2024, by and between the Registrant and Merck Sharp & Dohme LLC.8-K001-389434.112/19/2024
10.1#Personalis, Inc. 2011 Equity Incentive Plan, as amended, and forms of agreements thereunder.S-1333-23170310.15/23/2019
10.2#Personalis, Inc. 2019 Equity Incentive Plan and forms of agreements thereunder.S-1/A333-23170310.26/7/2019
10.3#Personalis, Inc. 2019 Employee Stock Purchase Plan.S-1/A333-23170310.36/7/2019
10.4#Personalis, Inc. 2020 Inducement Plan, as amended.10-K001-3894310.42/28/2024
10.5#Form of RSU Award Agreement under 2020 Inducement Plan.10-K001-3894310.52/28/2024
10.6#Form of Option Agreement under 2020 Inducement Plan.10-K001-3894310.62/28/2024
10.7#Form of Indemnification Agreement entered into by and between the Registrant and each director and executive officer.S-1/A333-23170310.46/7/2019
10.8#Amended and Restated Non-Employee Director Compensation Policy, dated February 27, 202410-Q001-3894310.15/8/2024
10.9#Amended and Restated Employment Agreement dated March 7, 2023, between the Company and Aaron Tachibana.8-K001-3894310.13/8/2023
10.10#Amended and Restated Offer Letter, dated March 7, 2023, between the Company and Christopher Hall.8-K001-3894310.23/8/2023
10.11#Amended and Restated Employment Agreement dated March 8, 2023, between the Company and Richard Chen.8-K001-3894310.33/8/2023
10.12#Second Amended and Restated Executive Severance Agreement, dated September 25, 2023, between the Company and Christopher Hall.10-K001-3894310.122/28/2024
10.13#Third Amended and Restated Executive Severance Agreement, dated September 25, 2023, between the Company and Aaron Tachibana.10-K001-3894310.132/28/2024
10.14#Third Amended and Restated Executive Severance Agreement, dated September 25, 2023, between the Company and Richard Chen.10-K001-3894310.142/28/2024
10.15#Second Amended and Restated Executive Severance Agreement, dated September 18, 2023, between the Company and Stephen Moore.10-K001-3894310.152/28/2024
10.16Ω‡Commercialization and Reference Laboratory Agreement, between the Registrant and Tempus AI, Inc., dated November 25, 2023.8-K001-3894310.111/28/2023
10.17Ω‡Amendment No. 1 to the Commercialization and Reference Laboratory Agreement, dated August 16, 2024, by and between the Registrant and Tempus AI, Inc.8-K001-3894310.18/16/2024
10.18Amendment No. 2 to the Commercialization and Reference Laboratory Agreement, dated September 20, 2024, by and between the Registrant and Tempus AI, Inc.10-Q001-3894310.211/6/2024
10.19Ω*Amendment No. 3 to the Commercialization and Reference Laboratory Agreement, dated December 13, 2024, by and between the Registrant and Tempus AI, Inc.
10.20Lease, by and between MENLO PREHC I, LLC, MENLO PREPI I, LLC, TPI INVESTORS 9, LLC and the Registrant, dated February 2, 2015.S-1333-23170310.95/23/2019
10.21First Amendment to Lease, by and between MENLO PREPI I, LLC and TPI INVESTORS 9, LLC and the Registrant, dated April 8, 2020.10-Q001-3894310.18/6/2020
10.22Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated August 25, 2021.10-Q001-3894310.111/4/2021
10.23Amendment No. 1 to Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated December 8, 2021.10-K001-3894310.162/24/2022
10.24Amendment No. 2 to Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated June 9, 2022.10-Q001-3894310.18/3/2022
10.25Amendment No. 3 to Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated December 19, 2022.10-K001-3894310.192/23/2023
10.26‡Contract No. 36C24E22D0031, by and between the U.S. Department of Veterans Affairs and the Registrant, dated September 30, 2022.10-Q001-3894310.111/2/2022
19.1*Insider Trading Policy.
21.1Subsidiaries of the Registrant as of December 31, 2024.
23.1Consent of Independent Registered Public Accounting Firm.
24.1Power of Attorney (included on the Signatures page of this Annual Report on Form 10-K).
31.1Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1†Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2†Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
97#Incentive Compensation Recoupment Policy.10-K001-38943972/28/2024
101*Inline XBRL Document Set for the consolidated financial statements and accompanying notes in Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K.
104*Inline XBRL for the cover page of this Annual Report on Form 10-K, included in the Exhibit 101 Inline XBRL Document Set.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.